Driver mutations in oncogenic pathways, rewiring of cellular metabolism and altered ROS
homoeostasis are intimately connected hallmarks of cancer. Electrons derived from different …

Recently, we presented evidence that high mitochondrial ATP production is a new
therapeutic target for cancer treatment. Using ATP as a biomarker, we isolated the …

In hypertrophied and failing hearts, fuel metabolism is reprogrammed to increase glucose
metabolism, especially glycolysis. This metabolic shift favors biosynthetic function at the …

Mitochondria are signaling hubs in cellular physiology that play a role in inflammatory
diseases. We found that partial inhibition of the mitochondrial ATP synthase in the intestine …

The mitochondrial protein IF1 binds to the catalytic domain of the ATP synthase and inhibits
ATP hydrolysis in ischemic tissues. Moreover, IF1 is overexpressed in many tumors and has …

Mitochondrial metabolism has emerged as a promising target against the mechanisms of
tumor growth. Herein, we have screened an FDA-approved library to identify drugs that …

In this contribution we summarize most of the findings reported for the molecular and cellular
biology of the physiological inhibitor of the mitochondrial H+-ATP synthase, the engine of …

Glioblastoma multiforme (GBM) is the most common and malignant of the primary adult brain
cancers. Ultrastructural and biochemical evidence shows that GBM cells exhibit …

The mitochondrial H+-ATP synthase synthesizes most of cellular ATP requirements by
oxidative phosphorylation (OXPHOS). The ATPase Inhibitory Factor 1 (IF1) is known to …

The ATPase Inhibitory Factor 1 (IF1) is the physiological inhibitor of the mitochondrial ATP
synthase. Herein, we summarize the regulation of the expression and activity of IF1 as a …